Form 4: Bristol-Myers Squibb Director Acquires Deferred Share Units

Director Theodore R. Samuels II acquired 966.37 deferred share units of Bristol-Myers Squibb on September 30, 2024, at a price of $51.74 per unit.

Summary

• On September 30, 2024, Theodore R. Samuels II, a director of Bristol-Myers Squibb, acquired 966.37 deferred share units.
• The price per deferred share unit was $51.74.
• These units will convert into shares of common stock upon settlement, which occurs when Samuels ceases to be a director or at a previously specified future date.
• Following the transaction, Samuels beneficially owns 51,297.97 shares, including deferred compensation and reinvested dividends.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of a director acquiring deferred share units. It indicates confidence but doesn't drastically alter the investment landscape.

Positives

• The acquisition of deferred share units by a director signals confidence in the company's future performance.

Future Outlook

The deferred share units will be converted into common stock upon settlement, either when Samuels leaves the board or at a predetermined date.

Industry Context

Form 4 filings are routine disclosures of insider transactions, providing transparency into the buying and selling activities of company insiders. This transaction reflects a director's ongoing investment in the company.

Stakeholder Impact

• The acquisition of deferred share units by a director can positively influence shareholder sentiment.

Key Dates